Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3705755 | 0.98 | PARP1 (0.48) | PARP1MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL14447536 | 0.88 | PARP1 (0.46) | PARP1MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL21174134 | 0.87 | NPC1 (0.55) | MAPK13RAF1MAPK9MAPK12MAPK11 | |
| SCHEMBL25881418 | 0.86 | NPC1 (0.57) | MAPK13RAF1MAPK9MAPK12MAPK11 | |
| SCHEMBL531889 | 0.79 | PARP1 (0.52) | PARP1MAPTALDH1A1PKMHPGD | |
| Hydrochloric Acid SCHEMBL1299145 | 0.78 | HTR2B (0.51) | PARP1KDM4EMAPTGFERALDH1A1 | |
| SCHEMBL17888854 | 0.76 | AKT1 (0.50) | PARP1MAPK11MAPK14ALDH1A1AKT1 | |
| SCHEMBL15767650 | 0.74 | NPC1 (0.48) | MAPK13RAF1MAPK9MAPK12MAPK11 | |
| SCHEMBL2708884 | 0.74 | MPO (0.54) | PARP1MAPK13RAF1MAPK9MAPK12 | |
| SCHEMBL7968676 | 0.74 | NPC1 (0.51) | PARP1MAPK13RAF1MAPK9MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240783-B1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | FAES FARMA SA (ES) | 2018-11-21 | — | — | EP | disclosed |
| US-10106522-B2 | Benzimidazole derivatives as antihistamine agents | FAES FARMA, S.A. (ES) | 2018-10-23 | — | — | US | disclosed |
| US-20180016251-A1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | FAES FARMA, S.A. (ES) | 2018-01-18 | — | — | US | disclosed |
| EP-3240783-A1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | FAES FARMA, S.A. (ES) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107848-A1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | FAES FARMA, S.A. (ES) | 2016-07-07 | — | — | WO | disclosed |
| EP-3040334-A1 | New benzimidazole derivatives as antihistamine agents | Faes Farma, S.A. (ES) | 2016-07-06 | — | — | EP | disclosed |
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957064-B2 | Fused pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130317002-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | US | disclosed |
| EP-2396331-B1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER IP GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091824-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016251-A1 | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS | HRH2, HRH4, HRH1 | PARP1 3138/4885MAPK13 904/4885RAF1 1820/4885 |
| US-20130317002-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, TYMS | PARP1 682/4885MAPK13 88/4885RAF1 253/4885 |
| US-10106522-B2 | Benzimidazole derivatives as antihistamine agents | HRH2, HRH1, HRH4 | PARP1 2834/4885MAPK13 1316/4885RAF1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.